DROTAVEX® 200 mg Capsules — Nifuroxazide — Intestinal Anti-Infective
1. Disclaimer
This monograph is intended for professional educational and reference purposes. It does not replace the current Egyptian-approved package leaflet, prescribing information, or individualized advice from a physician or pharmacist. Product labeling, indications, age restrictions, excipients, and regulatory status may change over time or differ between countries.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Management of acute diarrhea must primarily address hydration and the underlying cause. Nifuroxazide should not delay medical assessment when diarrhea is severe, persistent, bloody, febrile, associated with significant dehydration, or otherwise complicated. Oral rehydration is a cornerstone of treatment for acute infectious diarrhea, and antibacterial therapy is not routinely indicated for most uncomplicated cases.
2. Summary
DROTAVEX® is an oral preparation containing nifuroxazide 200 mg, a 5-nitrofuran intestinal anti-infective used for the short-term treatment of acute diarrhea of presumed bacterial origin when there are no clinical features suggesting invasive infection.
Oral rehydration solution (ORS), replacement of ongoing fluid and electrolyte losses, and continuation of appropriate nutrition remain fundamental components of treatment. Nifuroxazide is not a substitute for rehydration and should not be relied upon as sole therapy for invasive bacterial diarrhea or systemic infection.
Nifuroxazide is partially absorbed from the gastrointestinal tract, with approximately 10–20% of an oral dose absorbed, and is significantly metabolized. It also has a possible mutagenic potential. European regulatory product-information amendments state that nifuroxazide is not recommended during pregnancy or breastfeeding.
3. Brand Name
DROTAVEX®
Egyptian market listings identify a 200 mg, 36-capsule presentation.
4. Category
Pharmacotherapeutic category: Intestinal anti-infective / antidiarrheal agent.
Drug class: 5-nitrofuran derivative.
ATC code: A07AX03 – Nifuroxazide.
Nifuroxazide should not be regarded as a substitute for appropriate diagnostic assessment and systemic antimicrobial therapy when such treatment is clinically indicated.
5. Active Ingredient
Each hard gelatin capsule contains:
Nifuroxazide 200 mg
Reported inactive ingredients for DROTAVEX include maize starch, mannitol, polyvinylpyrrolidone, croscarmellose sodium, magnesium stearate, gelatin, Sunset Yellow, titanium dioxide, and quinoline yellow.
Patients with known hypersensitivity to nifuroxazide, nitrofuran derivatives, or any component of the formulation should not use the product. The excipient list should be checked against the current Egyptian commercial pack when clinically relevant.
6. Pharmaceutical Form & Strength
Pharmaceutical form: Hard gelatin capsule.
Strength: 200 mg nifuroxazide per capsule.
Route of administration: Oral.
The currently listed Egyptian commercial presentation contains 36 capsules, consistent with three units of 12 capsules.
7. Manufacturer & Marketing Authorization Holder
Manufacturer / marketing company in Egypt: EVA Pharma, Egypt.
Current Egyptian market sources identify DROTAVEX 200 mg, 36 capsules as an EVA Pharma product.
The exact current legal Marketing Authorization Holder name and address should be verified from the latest Egyptian Drug Authority-approved product information or current commercial pack.
8. Mechanism of Action
Nifuroxazide is a 5-nitrofuran antibacterial agent with predominantly local antibacterial activity within the intestinal lumen.
The precise mechanism of action is not fully established. Official nifuroxazide product information states that it probably inhibits bacterial dehydrogenase activity and bacterial protein synthesis. These mechanisms should therefore be regarded as proposed rather than completely defined.
9. Spectrum of Activity
Official product information for nifuroxazide reports local antibacterial activity against certain Gram-positive bacteria of the genus Staphylococcus and certain Gram-negative members of the Enterobacteriaceae, including Yersinia spp., Escherichia spp., Citrobacter spp., Enterobacter spp., Klebsiella spp., and Salmonella spp.
The same official SmPC reports no antibacterial activity against Proteus vulgaris, Proteus mirabilis, and Pseudomonas aeruginosa.
These reported spectrum data should not be interpreted as guaranteed clinical susceptibility or as a substitute for microbiological assessment when clinically indicated. Susceptibility may vary between organisms, strains, geographical regions, and over time.
10. Pharmacokinetics
Following oral administration, approximately 10–20% of nifuroxazide is absorbed from the gastrointestinal tract.
Nifuroxazide is significantly metabolized, and the principal drug-related moieties circulating in the blood are metabolites.
Its systemic bioavailability therefore remains relatively low, but gastrointestinal absorption should not be considered negligible.
11. Indications
DROTAVEX may be used for the short-term treatment of suspected acute diarrhea of bacterial origin in the absence of signs suggesting invasive infection, according to applicable product labeling.
Rehydration remains the primary supportive treatment. Many uncomplicated acute diarrheal illnesses are self-limited, and antibacterial treatment is not routinely required in most cases.
DROTAVEX should not be relied upon as sole treatment when diarrhea is associated with bloody stools, significant fever, severe abdominal symptoms, marked deterioration in general condition, sepsis, severe dehydration, or other manifestations suggesting invasive or systemic infection. Such presentations require medical assessment and, where appropriate, microbiological investigation and pathogen-directed treatment.
12. Administration
For the DROTAVEX 200 mg capsule presentation:
Patients aged 15 years and older:
1 capsule (200 mg) four times daily.
Maximum usual daily dose: 800 mg.
Treatment duration: Up to 3 days.
The capsule should be swallowed whole with an adequate amount of water.
Age restrictions for nifuroxazide differ between countries and formulations. The age limit applicable to DROTAVEX should therefore follow the current Egyptian product labeling rather than being extrapolated from other nifuroxazide products. For example, another official 200 mg nifuroxazide capsule SmPC permits one capsule every 6 hours from 7 years of age, demonstrating that age restrictions are product- and jurisdiction-specific.
13. Method of Preparation
No preparation or reconstitution is required for the capsule formulation.
Swallow the capsule whole with water.
During acute diarrhea, adequate oral rehydration solution (ORS) should be administered as appropriate to replace water and electrolytes. ORS is recommended as first-line therapy for mild-to-moderate dehydration. Severe dehydration, shock, altered mental status, or inability to tolerate oral fluids may require intravenous isotonic fluids.
Normal, appropriate food intake should generally be continued or resumed after rehydration rather than routinely imposing an unnecessarily restrictive diet. Fluid replacement should be individualized according to the degree of fluid loss and the patient's clinical condition.
14. Contraindications
DROTAVEX should not be used in patients with:
- Hypersensitivity to nifuroxazide.
- Hypersensitivity to other nitrofuran derivatives.
- Hypersensitivity to any excipient contained in the formulation.
- Any age-related contraindication or restriction stated in the current Egyptian DROTAVEX labeling.
Hypersensitivity to nifuroxazide, nitrofuran derivatives, or product excipients is also stated as a contraindication in official nifuroxazide product information.
15. Warnings & Precautions
Rehydration is essential. Nifuroxazide does not correct dehydration or electrolyte loss. ORS should be used when appropriate, and intravenous rehydration should be considered in severe dehydration or when adequate oral replacement is not possible.
Medical advice should be sought if diarrhea persists for more than approximately 2 days of treatment, fails to improve, or worsens. Treatment should not be prolonged beyond the recommended short course without reassessing the diagnosis and the patient's hydration status.
Bloody diarrhea, significant fever, severe abdominal pain or cramping, severe or persistent vomiting, marked systemic illness, signs of sepsis, or severe dehydration require medical assessment. The need for systemic antimicrobial treatment depends on the suspected or identified pathogen and the clinical circumstances and should not be assumed solely from the presence of bloody diarrhea.
In particular, empiric systemic antibacterial therapy is not routinely recommended for bloody diarrhea in otherwise immunocompetent patients while diagnostic evaluation is pending, except in defined clinical circumstances. Antimicrobial therapy should be avoided in infections caused by STEC O157 and other Shiga toxin 2-producing STEC, or when the toxin genotype is unknown, because of potential harm.
Discontinue nifuroxazide and seek medical assistance if hypersensitivity develops, particularly generalized rash, urticaria, swelling of the face, lips or tongue, difficulty breathing, angioedema, or anaphylaxis.
Many cases of acute gastroenteritis are viral or otherwise self-limiting. Nifuroxazide has no established therapeutic role against viral gastroenteritis.
16. Drug Interactions
DROTAVEX-specific clinical interaction information is limited.
Official prescribing information for some other nifuroxazide products advises avoiding alcohol during treatment, because alcohol may cause a disulfiram-like reaction.
The same official product information advises against taking other oral medicines simultaneously with nifuroxazide because of its reported adsorptive properties, which may interfere with their gastrointestinal availability.
These interaction precautions originate from nifuroxazide product information in other jurisdictions and should not be interpreted as a substitute for the current DROTAVEX Egyptian prescribing information. Patients using clinically important oral medicines should consult a physician or pharmacist.
17. Side Effects
Nifuroxazide is generally administered for a short period, but adverse reactions can occur.
Reported adverse reactions include:
- Immune/allergic reactions: rash, urticaria, angioedema and anaphylactic shock; frequency cannot always be estimated from available data.
- Gastrointestinal reactions: abdominal pain, nausea, and worsening of diarrhea have been reported in individual cases of hypersensitivity.
- Skin reactions: rash has been reported; isolated cases of pustular eruption and prurigo nodularis associated with contact allergy have also been described.
- Hematologic reactions: an isolated case of granulocytopenia has been reported.
These adverse reactions are documented in official nifuroxazide product information.
Treatment should be discontinued and urgent medical attention obtained if a severe hypersensitivity reaction is suspected.
18. Use in Special Populations
Pregnancy:
Nifuroxazide is not recommended during pregnancy. Human pregnancy data are limited, animal reproductive toxicity studies are insufficient, and nifuroxazide demonstrates possible mutagenic potential.
Women of childbearing potential:
Nifuroxazide should not be used in women of childbearing potential who are not using effective contraception, according to European regulatory product-information recommendations.
Breastfeeding:
Treatment during breastfeeding is not recommended. It is unknown whether nifuroxazide or its metabolites are excreted into human breast milk. Although systemic bioavailability is relatively low, an effect on the gastrointestinal microbiome of the breastfed infant cannot be excluded.
Fertility:
There is insufficient information from animal studies to determine the effect of nifuroxazide on fertility.
Children and adolescents:
Age restrictions vary between nifuroxazide products and jurisdictions. For DROTAVEX 200 mg capsules, follow the current Egyptian product labeling; dosing from pediatric suspensions or foreign capsule products should not automatically be extrapolated to DROTAVEX.
Older adults / renal or hepatic impairment:
No specific DROTAVEX dosing recommendation for these populations has been established in the information reviewed. Clinical assessment is especially important when acute diarrhea is accompanied by dehydration, comorbidity, renal impairment, or significant systemic illness.
19. Storage Conditions
Store in a dry place at a temperature not exceeding 30°C, according to the stated DROTAVEX storage information.
Protect from inappropriate heat and moisture.
Keep out of the sight and reach of children.
Always follow the storage conditions printed on the current commercial pack if they differ.
20. Additional Sections
Effects on ability to drive and use machines:
Nifuroxazide is not expected to impair the ability to drive or operate machinery. Official nifuroxazide product information states that it has no effect on the ability to drive and use machines.
Overdose:
Detailed information on nifuroxazide overdose is limited. In suspected overdose, the patient should be monitored carefully and treatment should be symptomatic and supportive.
Preclinical safety:
Nifuroxazide demonstrates possible mutagenic potential. Its carcinogenic potential has been investigated in two-year studies in mice and rats; carcinogenicity was not demonstrated under the conditions of those studies.
Packaging:
The currently listed Egyptian presentation is DROTAVEX 200 mg – 36 hard capsules, manufactured/marketed by EVA Pharma.
21. Frequently Asked Questions (FAQ)
Is DROTAVEX a substitute for oral rehydration solution?
No. Fluid and electrolyte replacement is fundamental in acute diarrhea. ORS is first-line therapy for mild-to-moderate dehydration.
Can DROTAVEX be used for every case of diarrhea?
No. Many cases of acute diarrhea are viral or self-limiting and do not require antibacterial therapy. Nifuroxazide is intended for selected cases consistent with its approved indication and should not delay investigation of severe or invasive disease.
What symptoms require medical assessment rather than continued self-treatment?
Bloody stools, significant fever, severe or worsening abdominal symptoms, repeated vomiting, signs of dehydration, marked weakness, altered consciousness, systemic illness, signs of sepsis, or persistent diarrhea warrant medical evaluation.
Does bloody diarrhea always require an antibiotic?
No. Bloody diarrhea requires appropriate clinical assessment and may require microbiological testing. Empiric antibiotics are not routinely recommended in all immunocompetent patients, and antimicrobial therapy should be avoided in STEC O157 and other Shiga toxin 2-producing STEC infections because of potential harm.
Can DROTAVEX be used during pregnancy?
Nifuroxazide is not recommended during pregnancy because human data are limited and it has possible mutagenic potential.
Can it be used while breastfeeding?
Treatment with nifuroxazide during breastfeeding is not recommended because adequate clinical experience is lacking and an effect on the breastfed infant's gastrointestinal microbiome cannot be excluded.
Can alcohol be consumed during treatment?
Some official nifuroxazide product information advises avoiding alcohol because a disulfiram-like reaction may occur.
What should be done if symptoms do not improve?
Seek medical advice if diarrhea persists beyond approximately 2 days of treatment, worsens earlier, or if features of severe or invasive disease occur. The recommended DROTAVEX course should not be prolonged beyond 3 days without appropriate medical reassessment.
22. References
- European Medicines Agency / CMDh – Nifuroxazide PSUSA/00002160/202108. Scientific conclusions and amendments to product information concerning gastrointestinal absorption, metabolism, pregnancy, breastfeeding, fertility, mutagenic potential, and carcinogenicity; CMDh position adopted in 2022.
- Official Polish Register of Medicinal Products – Nifuroksazyd Gedeon Richter 200 mg hard capsules, Summary of Product Characteristics. Source for pharmacodynamics, antibacterial spectrum, pharmacokinetics, interactions, adverse reactions, overdose, and driving information.
- Infectious Diseases Society of America (IDSA). Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Source for rehydration, investigation of febrile/bloody diarrhea, indications for antimicrobial treatment, and avoidance of antimicrobials in STEC O157/Shiga toxin 2-producing infections.
- Egyptian market information for DROTAVEX 200 mg, 36 capsules. Current listings identify nifuroxazide as the active ingredient and EVA Pharma as the manufacturer/marketing company; these listings are used for product-identification and pack information rather than as primary clinical evidence.
- Current Egyptian-approved DROTAVEX package information. This remains the controlling reference for Egypt-specific age restrictions, excipients, storage instructions, legal Marketing Authorization Holder details, and any product-specific precautions when available.